Ryan Haumschild, PharmD, MS, MBA, leads a discussion surrounding myelodysplastic syndrome (MDS).

Medical experts provide an overview on potential risk factors leading to MDS.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA, provides insight on the impact myelodysplastic syndrome has on patients’ quality of life.

Robert Mancini, PharmD, BCOP, FHOPA, highlights differentiating diagnoses similar to myelodysplastic syndrome and discusses the International Prognostic Scoring System (IPSS).

Experts outline treatment goals for patients diagnosed with MDS.

A panel of medical experts discuss supportive care needs for patients with myelodysplastic syndrome.

Drs Mahmoudjafari and Mancini evaluate MDS treatment pathways and offer potential needs for switching treatment strategies.

Key opinion leaders discuss how quality of life is impacted by refractory anemia and treatment toxicity in patients with MDS.

Dr Mahmoudjafari shares considerations for incorporating oral agents into MDS treatment landscape.

Dr Mancini navigates challenges inhibiting patients to receive optimal care amid diagnosis of MDS.

Drs Mancini and Mahmoudjafari discuss NCCN Guidelines affecting treatment strategies for patients with MDS.

The panel of experts provide their closing thoughts, highlighting unmet needs and treatments on the horizon for MDS.